文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.

作者信息

Kosmidou Vivian, Oikonomou Eftychia, Vlassi Margarita, Avlonitis Spyros, Katseli Anastasia, Tsipras Iraklis, Mourtzoukou Despina, Kontogeorgos Georgios, Zografos Georgios, Pintzas Alexander

机构信息

Laboratory of Signal Mediated Gene Expression, Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, 11635, Greece.

出版信息

Hum Mutat. 2014 Mar;35(3):329-40. doi: 10.1002/humu.22496. Epub 2014 Jan 15.


DOI:10.1002/humu.22496
PMID:24352906
Abstract

Current clinical problems in colorectal cancer (CRC) diagnostics and therapeutics include the disease complexity, tumor heterogeneity, and resistance to targeted therapeutics. In the present study, we examined 171 CRC adenocarcinomas from Greek patients undergoing surgery for CRC to determine the frequency of KRAS, BRAF, and PIK3CA point mutations from different areas of tumors in heterogeneous specimens. Ninety two out of 171 (53.8%) patients were found to bear a KRAS mutation in codons 12/13. Of the 126 mutations found, 57.9% (73/126) were c.38G>A mutations (p.G13D) and 22.2% (28/126) were c.35G>T (p.G12V). Remarkably, RAS mutations in both codons 12 and 13 were recorded in the same tumor by pyrosequencing. Moreover, differences in KRAS mutations between tumor center and periphery revealed tumor heterogeneity in 50.7% of the specimens. BRAF c.1799T>A (V600E) mutations were moderately detected in 4/171 (2.3%) specimens, whereas most PIK3CA mutations were revealed by pyrosequencing 6/171 (3.5%). Remarkable tumor heterogeneity is revealed, where double mutations of KRAS in the same tumor and different KRAS mutation status between tumor core and margin are detected with high frequency. It is expected that these findings will have a major impact in cancer diagnosis and personalized therapies.

摘要

相似文献

[1]
Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.

Hum Mutat. 2014-3

[2]
[Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].

Zhonghua Bing Li Xue Za Zhi. 2012-9

[3]
KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.

Oncol Rep. 2011-3-17

[4]
Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.

Med Oncol. 2014-9

[5]
Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.

Int J Clin Exp Pathol. 2014-8-15

[6]
BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.

BMC Cancer. 2014-11-3

[7]
Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.

Int J Biol Markers. 2012-12-27

[8]
[Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].

Zhonghua Bing Li Xue Za Zhi. 2012-9

[9]
Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.

Clin Cancer Res. 2012-7-2

[10]
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.

Am J Clin Pathol. 2008-8

引用本文的文献

[1]
Search for Mutations Connected With Non-Response to Anti-EGFR Therapy in mCRC in the Morphologically Defined Regions of Primary Tumours.

Cancer Med. 2025-5

[2]
and Mutation Rates and Survival Outcomes in Colorectal Cancer in an Ethnically Diverse Patient Cohort.

Int J Mol Sci. 2023-12-15

[3]
Exploring Better Strategies for RAS Mutation-Associated EGFR-Targeted Resistance in Colorectal Cancer: From the Perspective of Cancer Community Ecology.

Front Oncol. 2021-10-22

[4]
Multi-ancestral origin of intestinal tumors: Impact on growth, progression, and drug efficacy.

Cancer Rep (Hoboken). 2022-2

[5]
Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements.

Int J Mol Sci. 2020-12-24

[6]
High frequency of microsatellite instability and its substantial co-existence with and mutations in Vietnamese patients with colorectal cancer.

Oncol Lett. 2021-1

[7]
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.

Mol Oncol. 2019-9-30

[8]
Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review.

Curr Colorectal Cancer Rep. 2019-4

[9]
Biology of Nodal Spread in Colon Cancer: Insights from Molecular and Genetic Studies.

Eur Surg Res. 2018

[10]
Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate.

J Cancer Res Clin Oncol. 2018-10-27

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索